An evaluation of the drug-drug interaction between proton-pump inhibitors and EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients.

被引：0
|
作者：
Chan, Alexandre
Chen, Bingrong
Ng, Raymond [2 ]
Yong, Wei-Peng [1 ]
Ko, Yu
机构：
[1] Natl Univ Singapore, Inst Canc, Singapore 117548, Singapore
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
PHARMACOTHERAPY | 2012年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：E221 / E222
页数：2
相关论文
共 50 条
  • [31] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [32] Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
    Maevskaya, J.
    Laktionov, K.
    Yudin, D.
    Vladimirova, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1402 - S1402
  • [33] Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer
    Gulikers, Judith L.
    Otten, Leila-Sophie
    Hendriks, Lizza E. L.
    Winckers, Kristien
    Henskens, Yvonne
    Leentjens, Jenneke
    van den Heuvel, Michel M.
    ter Heine, Rob
    Croes, Sander
    Piet, Berber
    van Geel, Robin M. J. M.
    BRITISH JOURNAL OF CANCER, 2024, 131 (02) : 299 - 304
  • [34] Drug-drug interaction in patients using proton pump inhibitors: a patient drug profile study
    Karasakal, Y. E.
    Sancar, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 483 - 483
  • [35] Agreement of Different Drug-Drug Interaction Checkers for Proton Pump Inhibitors
    Carollo, Massimo
    Crisafulli, Salvatore
    Selleri, Margherita
    Piccoli, Luca
    L'Abbate, Luca
    Trifiro, Gianluca
    JAMA NETWORK OPEN, 2024, 7 (07) : e2419851
  • [36] Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    de Bruin, Elza C.
    Cowell, Catherine F.
    Howell, Michael
    Varmus, Harold E.
    Politi, Katerina
    Downward, Julian
    CANCER RESEARCH, 2011, 71
  • [37] Drug-drug interactions in patients receiving tyrosine kinase inhibitors
    Keller, Kristine L.
    Franquiz, Miguel J.
    Duffy, Alison P.
    Trovato, James A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (02) : 110 - 115
  • [38] Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Min Jae
    Yi, Jun Ho
    Kim, Tae Sung
    Chung, Myung Jin
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    LUNG CANCER, 2010, 69 (01) : 105 - 109
  • [39] Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [40] Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
    Jia, Caiyan
    Xu, Qian
    Zhao, Lu
    Kong, Fanming
    Jia, Yingjie
    TRANSLATIONAL ONCOLOGY, 2024, 39
12345